SABS (SAB Biotherapeutics) General and Admin. Expense: $18.09 Mil (TTM As of Mar. 2026)


SABS SAB Biotherapeutics Inc SABS
26 GF Score
Price $3.80
! 2 Warning Signs
View Full Analysis

What is SAB Biotherapeutics General and Admin. Expense?

SAB Biotherapeutics SABS -1.81% 26 General and Admin. Expense is $18.09 Mil as of Mar. 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. SAB Biotherapeutics's General and Admin. Expense for the three months ended in Mar. 2026 was $6.60 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $18.09 Mil.

SAB Biotherapeutics General and Admin. Expense Related Terms

SAB Biotherapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for SAB Biotherapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SAB Biotherapeutics General and Admin. Expense Chart

SAB Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial 17.09 16.38 23.80 13.98 14.60

SAB Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.12 2.74 3.71 5.04 6.60
SABS
26GF Score
SAB Biotherapeutics Inc SABS
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SAB Biotherapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $18.09 Mil mean?
SAB Biotherapeutics (SABS) has a General and Admin. Expense of $18.09 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on SAB Biotherapeutics and its competitors.
Is SAB Biotherapeutics' General and Admin. Expense too high?
SAB Biotherapeutics' current General and Admin. Expense is $18.09 Mil. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' General and Admin. Expense compare to TRDA and ACIU?
SAB Biotherapeutics' General and Admin. Expense of $18.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current General and Admin. Expense is $18.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current General and Admin. Expense of $18.09 Mil. The current General and Admin. Expense is $18.09 Mil. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current General and Admin. Expense is $18.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SAB Biotherapeutics Business Description

Address 777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score

Get the complete analysis for SABS

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.80
Price